Enliven Therapeutics (ELVN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on the stock and has a $38.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sam Slutsky’s rating is based on the promising potential of Enliven Therapeutics’ lead program, ELVN-001, which is currently in Phase 1 development for treating chronic myeloid leukemia (CML). The drug has shown a 24-week major molecular response (MMR) achievement rate of 26%, which is higher than the rate observed in a similar Phase 1 trial of Scemblix. This suggests a favorable potential effect size for future studies.
Moreover, ELVN-001 has demonstrated a strong safety profile, with no significant arterial occlusive events, a common issue with other treatments. The company is also planning to expand the study to include earlier line patients, indicating confidence in the drug’s efficacy and safety. These factors, combined with the company’s strategic planning for future regulatory meetings, contribute to the Buy rating.